

## **Product datasheet for TL306937**

#### OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

## Adracalin (AAAS) Human shRNA Plasmid Kit (Locus ID 8086)

### **Product data:**

**Product Type:** shRNA Plasmids

Product Name: Adracalin (AAAS) Human shRNA Plasmid Kit (Locus ID 8086)

Locus ID: 8086

Synonyms: AAA; AAASb; ADRACALA; ADRACALIN; ALADIN; GL003

Vector:pGFP-C-shLenti (TR30023)E. coli Selection:Chloramphenicol (34 ug/ml)

**Mammalian Cell** 

Selection:

Puromycin

Format: Lentiviral plasmids

**Components:** AAAS - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 8086).

5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.

**RefSeq:** <u>NM 001173466, NM 015665, NM 015665.1, NM 015665.2, NM 015665.3, NM 015665.4,</u>

NM 015665.5, NM 001173466.1, BC000659, BC000659.2, BC018836, NM 001173466.2

UniProt ID: O9NRG9

**Summary:** The protein encoded by this gene is a member of the WD-repeat family of regulatory proteins

and may be involved in normal development of the peripheral and central nervous system. The encoded protein is part of the nuclear pore complex and is anchored there by NDC1. Defects in this gene are a cause of achalasia-addisonianism-alacrima syndrome (AAAS), also called triple-A syndrome or Allgrove syndrome. Two transcript variants encoding different

isoforms have been found for this gene. [provided by RefSeq, Mar 2010]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.







# Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).